Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …

Platinum-based doublet chemotherapy with or without bevacizumab is the standard of care
for the initial management of advanced and metastatic non-small cell lung cancer (NSCLC) …

The development of personalized medicine with a focus on novel targeted therapies has
supplanted the one-size-fits-all approach to the treatment of many cancers, including non …

Despite advances in the management of non-small-cell lung cancer (NSCLC), including the
introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase …

The rapid evolution of treatment for advanced lung cancer is a story of how scientists have
struggled to move from nonselective cytotoxic chemotherapy to personalized precision …

Non-small-cell lung cancer (NSCLC) is a leading cause of malignancy-related mortality in
the Western world. Despite advances in early detection and standard treatment, NSCLC is …

Innovative therapeutic agents have significantly improved outcome with an acceptable
safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, who …

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for
almost 80%–85% of all lung cancer cases. Unfortunately, more than half of the patients will …

Non-small cell lung cancer (NSCLC) remains by far the single most common malignancy of
lung cancer which causes more and more mortality in recent years. NSCLC accounts for …

With rare exceptions, attempts to combine so-called targeted agents with standard cytotoxic
chemotherapy in advanced non–small cell lung cancer have yielded disappointing results …